Form 4 for TXG 10x Genomics, Inc.
Accepted 2022-09-14 00:00:00 ET · period of report 2022-09-12 · accession 0001567619-22-017433 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-09-14 | 2022-09-12 | TXG | Saxonov Serge | CEO, Dir | M - OptEx | $1.20 | +11.5K | 977.6K | +1% | +$13.8K |
| D | 2022-09-14 | 2022-09-12 | TXG | Saxonov Serge | CEO, Dir | M - OptEx | $0.00 | -11.5K | 41.0K | -22% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2022-09-12 | M | A | 11,500 | $1.20 | 977,602 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2022-09-12 | M | D | 11,500 | $0.00 | 41,035 | D | $1.20 · — to 2027-10-18 | 11,500 Class A Common Stock | (F3) This option, originally for 300,000 shares, of which 258,965 have been exercised, vested as to 1/48th of the shares on October 1, 2017, and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. |